Clinical Trial Update: A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab plus brentuximab vedotin vs brentuximab vedotin alone in advanced stage classical Hodgkin lymphoma; trial terminated with post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hodgkin's Disease | Phase 3 | Status: TERMINATED | Results posted: 2022-04-12